Literature DB >> 28664433

Factors influencing the outcome of magnetic sphincter augmentation for chronic gastroesophageal reflux disease.

Heather F Warren1, Lisa M Brown2, Matias Mihura3, Alexander S Farivar3, Ralph W Aye3, Brian E Louie4.   

Abstract

OBJECTIVES: Magnetic sphincter augmentation (MSA) is a surgical treatment option for patients with gastroesophageal reflux disease (GERD). MSA consistently improves quality of life, maintains freedom from PPIs, and objectively controls GERD. However, up to 24% of patients did not achieve these outcomes. We sought to identify factors predicting outcomes after MSA placement with the aim of refining selection criteria.
METHODS: We retrospectively analyzed clinical, endoscopic, manometric, pH data, and intraoperative factors from two databases: Pivotal Trial (N = 99) and our prospectively maintained esophageal database (N = 71). A priori outcomes were defined as excellent (GERD-HRQL <5, no PPI, no esophagitis), good (GERD-HRQL 6-15, no PPI, grade A esophagitis), fair (GERD-HRQL 16 to 25, PPI use, grade B esophagitis), and poor (GERD-HRQL >25, PPI use, grade C/D esophagitis). Univariable and multivariable logistic regression analyses were performed to determine predictors of achieving an excellent/good outcome.
RESULTS: A total of 170 patients underwent MSA with a median age of 53 years, [43-60] and a median BMI of 27 (IQR = 24-30). At baseline, 93.5% of patients experienced typical symptoms and 69% atypical symptoms. Median DeMeester score was 37.9 (IQR 27.9-51.2) with a structurally intact sphincter in 47%. Esophagitis occurred in 43%. At 48 [19-60] months after MSA, excellent outcomes were achieved in 47%, good in 28%, fair in 22%, and poor in 3%. Median DeMeester score was 15.6 (IQR = 5.8-26.6), esophagitis in 17.6% and daily PPI use in 17%. At univariable analysis, excellent/good outcomes were negatively impacted by BMI, preoperative LES residual pressure, Hill grade, and hiatal hernia. At multivariable analysis, BMI >35 (OR = 0.05, 0.003-0.78, p = 0.03), structurally defective LES (OR = 0.37, 0.13-0.99, p = 0.05), and preoperative LES residual pressure (OR = 0.89, 0.80-0.98, p = 0.02) were independent negative predictors of excellent/good outcome.
CONCLUSIONS: Magnetic sphincter augmentation results in excellent/good outcomes in most patients but a higher BMI, structurally defective sphincter, and elevated LES residual pressure may prevent this goal.

Entities:  

Keywords:  Esophagitis; Gastroesophageal reflux disease; LINX; Magnetic sphincter augmentation; Postoperative outcomes; Proton pump inhibitors; Quality of life

Mesh:

Substances:

Year:  2017        PMID: 28664433     DOI: 10.1007/s00464-017-5696-5

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  22 in total

1.  Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication.

Authors:  G M Campos; J H Peters; T R DeMeester; S Oberg; P F Crookes; S Tan; S R DeMeester; J A Hagen; C G Bremner
Journal:  J Gastrointest Surg       Date:  1999 May-Jun       Impact factor: 3.452

Review 2.  Epidemiology of gastro-oesophageal reflux disease: a systematic review.

Authors:  J Dent; H B El-Serag; M-A Wallander; S Johansson
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

Review 3.  LINX® magnetic esophageal sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: a systematic review and meta-analysis.

Authors:  Daniel Skubleny; Noah J Switzer; Jerry Dang; Richdeep S Gill; Xinzhe Shi; Christopher de Gara; Daniel W Birch; Clarence Wong; Matthew M Hutter; Shahzeer Karmali
Journal:  Surg Endosc       Date:  2016-12-15       Impact factor: 4.584

4.  One hundred consecutive patients treated with magnetic sphincter augmentation for gastroesophageal reflux disease: 6 years of clinical experience from a single center.

Authors:  Luigi Bonavina; Greta Saino; Davide Bona; Andrea Sironi; Veronica Lazzari
Journal:  J Am Coll Surg       Date:  2013-07-12       Impact factor: 6.113

5.  Laparoscopic Magnetic Sphincter Augmentation vs Laparoscopic Nissen Fundoplication: A Matched-Pair Analysis of 100 Patients.

Authors:  Jessica L Reynolds; Joerg Zehetner; Phil Wu; Shawn Shah; Nikolai Bildzukewicz; John C Lipham
Journal:  J Am Coll Surg       Date:  2015-03-05       Impact factor: 6.113

6.  Obesity is associated with increased transient lower esophageal sphincter relaxation.

Authors:  Justin Che-Yuen Wu; Lik-Man Mui; Carrian Man-Yuen Cheung; Yawen Chan; Joseph Jao-Yiu Sung
Journal:  Gastroenterology       Date:  2006-12-19       Impact factor: 22.682

7.  Short-term outcomes using magnetic sphincter augmentation versus Nissen fundoplication for medically resistant gastroesophageal reflux disease.

Authors:  Brian E Louie; Alexander S Farivar; Dale Shultz; Christina Brennan; Eric Vallières; Ralph W Aye
Journal:  Ann Thorac Surg       Date:  2014-06-21       Impact factor: 4.330

8.  Impaired esophageal function in morbidly obese patients with gastroesophageal reflux disease: evaluation with multichannel intraluminal impedance.

Authors:  E Quiroga; F Cuenca-Abente; D Flum; E P Dellinger; B K Oelschlager
Journal:  Surg Endosc       Date:  2006-03-16       Impact factor: 4.584

9.  Multi-institutional outcomes using magnetic sphincter augmentation versus Nissen fundoplication for chronic gastroesophageal reflux disease.

Authors:  Heather F Warren; Jessica L Reynolds; John C Lipham; Joerg Zehetner; Nikolai A Bildzukewicz; Paul A Taiganides; Jody Mickley; Ralph W Aye; Alexander S Farivar; Brian E Louie
Journal:  Surg Endosc       Date:  2015-11-05       Impact factor: 4.584

10.  Length and pressure of the reconstructed lower esophageal sphincter is determined by both crural closure and Nissen fundoplication.

Authors:  Brian E Louie; Seema Kapur; Maurice Blitz; Alexander S Farivar; Eric Vallières; Ralph W Aye
Journal:  J Gastrointest Surg       Date:  2012-11-27       Impact factor: 3.452

View more
  7 in total

1.  A budget impact analysis of a magnetic sphincter augmentation device for the treatment of medication-refractory mechanical gastroesophageal reflux disease: a United States payer perspective.

Authors:  John Pandolfino; John Lipham; Amarpreet Chawla; Nicole Ferko; Andrew Hogan; Rana A Qadeer
Journal:  Surg Endosc       Date:  2019-09-26       Impact factor: 4.584

Review 2.  Magnetic sphincter augmentation for gastroesophageal reflux disease: review of clinical studies.

Authors:  Emanuele Asti; Alberto Aiolfi; Veronica Lazzari; Andrea Sironi; Matteo Porta; Luigi Bonavina
Journal:  Updates Surg       Date:  2018-07-18

Review 3.  Comparison of the outcome of laparoscopic procedures for GERD.

Authors:  Fabrizio Rebecchi; Marco Ettore Allaix; Lorenzo Cinti; Milica Nestorović; Mario Morino
Journal:  Updates Surg       Date:  2018-07-19

4.  Does Treatment of the Hiatus Influence the Outcomes of Magnetic Sphincter Augmentation for Chronic GERD?

Authors:  Matías Mihura Irribarra; Sandra Blitz; Candice L Wilshire; Anee Sophia Jackson; Alexander S Farivar; Ralph W Aye; Christy M Dunst; Brian E Louie
Journal:  J Gastrointest Surg       Date:  2019-03-15       Impact factor: 3.452

5.  Safety and efficacy of magnetic sphincter augmentation dilation.

Authors:  Reid Fletcher; Christy M Dunst; Walaa F Abdelmoaty; Evan T Alicuben; Ealaf Shemmeri; Brett Parker; Dolores Müller; Ahmed M Sharata; Kevin M Reavis; Daniel Davila Bradley; Nikolai A Bildzukewicz; Brian E Louie; John C Lipham; Steven R DeMeester
Journal:  Surg Endosc       Date:  2020-07-15       Impact factor: 4.584

6.  Systematic review of the introduction and evaluation of magnetic augmentation of the lower oesophageal sphincter for gastro-oesophageal reflux disease.

Authors:  E N Kirkham; B G Main; K J B Jones; J M Blazeby; N S Blencowe
Journal:  Br J Surg       Date:  2019-12-04       Impact factor: 6.939

7.  Magnetic Sphincter Augmentation and Postoperative Dysphagia: Characterization, Clinical Risk Factors, and Management.

Authors:  Shahin Ayazi; Ping Zheng; Ali H Zaidi; Kristy Chovanec; Nobel Chowdhury; Madison Salvitti; Yoshihiro Komatsu; Ashten N Omstead; Toshitaka Hoppo; Blair A Jobe
Journal:  J Gastrointest Surg       Date:  2019-08-06       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.